MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/1759-7714.70209

Медицинская библиотека · Thoracic cancer · 2025

Salvage Surgery Following Systemic Therapy in Initially Unresectable Non-Small Cell Lung Cancer.

Seto Katsutoshi, Horio Yoshitsugu, Masago Katsuhiro, Sasaki Eiichi, Kuroda Hiroaki, Matsubayashi Yuta, Iwashimizu Hisanori, Noritake Osamu, Sato Keiyu, Matsui Takuya, Suzuki Soichiro, Shimizu Junichi, Fujiwara Yutaka, Sakakura Noriaki

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

This study evaluated the safety, long-term survival, and prognostic factors associated with salvage pulmonary surgery following systemic therapy for initially unresectable non-small cell lung cancer (NSCLC).

METHODS

Between 2014 and 2024, this single-center retrospective review identified 32 patients (median age: 61.0 years) with NSCLC initially considered unresectable who subsequently underwent curative-intent pulmonary resection after chemotherapy, targeted therapy, and/or immunotherapy. The primary endpoint was overall survival (OS); secondary endpoints included recurrence-free survival (RFS), major morbidity (Clavien-Dindo grade ≥ IIIa), and R0 resection rate. The Kaplan-Meier method and log-rank test were employed.

RESULTS

Reasons for unresectability at initial diagnosis were distant metastasis (n = 20; 62.5%), N3 nodal disease (n = 6; 18.8%), bulky N2 nodal disease (n = 3; 9.4%), and tumor or nodal extension requiring pneumonectomy (n = 3; 9.4%). Overall, 65.6% patients underwent lobectomy, with R0 resection achieved in 81.3% and pathological complete or major response observed in 15.6%. Overall complication and major morbidity rates were 12.5% and 3.1%, respectively; no 90-day mortality was observed. After a median follow-up of 40.1 months, median OS was not reached, whereas median RFS was 49.9 months; 5-year OS and RFS were 75.0% (95% CI 51.6-88.3) and 46.3% (95% CI 26.3-64.2), respectively. Notably, adenocarcinoma histology was significantly more prevalent in the good-prognosis group (88.9% vs. 35.7%, p = 0.003).

CONCLUSIONS

Salvage pulmonary surgery following systemic therapy is safe, yielding a 5-year OS rate of 75% in carefully selected patients with advanced NSCLC. Prevalent adenocarcinoma histology in the good-prognosis cohort is associated with superior outcomes.

Для цитирования: Seto Katsutoshi, Horio Yoshitsugu, Masago Katsuhiro, Sasaki Eiichi, Kuroda Hiroaki, Matsubayashi Yuta, Iwashimizu Hisanori, Noritake Osamu, Sato Keiyu, Matsui Takuya, Suzuki Soichiro, Shimizu Junichi, Fujiwara Yutaka, Sakakura Noriaki. Salvage Surgery Following Systemic Therapy in Initially Unresectable Non-Small Cell Lung Cancer.. Thoracic cancer. 2025. DOI: 10.1111/1759-7714.70209.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.